DK1363668T3 - Kombinationer af galdesyrekompleksdanner(e) og sterolabsorptionsinhibitor(er) og behandling af vaskulære indikationer - Google Patents

Kombinationer af galdesyrekompleksdanner(e) og sterolabsorptionsinhibitor(er) og behandling af vaskulære indikationer

Info

Publication number: DK1363668T3
Authority: DK; Denmark
Prior art keywords: combinations; treatment; complexing agent; bile acid; absorption inhibitor
Prior art date: 2001-01-26

Application number

DK02707556T

Other languages

Danish (da)

English (en)

Inventor

Harry R Davis

Teddy Kosoglou

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-01-26

Filing date

2002-01-25

Publication date

2007-11-05

2002-01-25 Application filed by Schering Corp filed Critical Schering Corp

2007-11-05 Application granted granted Critical

2007-11-05 Publication of DK1363668T3 publication Critical patent/DK1363668T3/da

Links

HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 title 1
229930182558 Sterol Natural products 0.000 title 1
238000010521 absorption reaction Methods 0.000 title 1
239000003613 bile acid Substances 0.000 title 1
239000008139 complexing agent Substances 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
150000003432 sterols Chemical class 0.000 title 1
235000003702 sterols Nutrition 0.000 title 1
230000002792 vascular Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Molecular Biology (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

DK02707556T 2001-01-26 2002-01-25 Kombinationer af galdesyrekompleksdanner(e) og sterolabsorptionsinhibitor(er) og behandling af vaskulære indikationer DK1363668T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US26460001P	2001-01-26	2001-01-26
US32384201P	2001-09-21	2001-09-21
PCT/US2002/002010 WO2002058733A2 (fr)	2001-01-26	2002-01-25	Combinaisons de chelateur(s) des acides biliaires et d'inhibiteur(s) d'absorption des sterols, et traitements pour troubles vasculaires

Publications (1)

Publication Number	Publication Date
DK1363668T3 true DK1363668T3 (da)	2007-11-05

Family

ID=26950649

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK02707556T DK1363668T3 (da)	2001-01-26	2002-01-25	Kombinationer af galdesyrekompleksdanner(e) og sterolabsorptionsinhibitor(er) og behandling af vaskulære indikationer

Country Status (16)

Country	Link
US (2)	US20030053981A1 (fr)
EP (2)	EP1785144A3 (fr)
JP (1)	JP2004521894A (fr)
AR (1)	AR035739A1 (fr)
AT (1)	ATE369851T1 (fr)
AU (1)	AU2002241956A1 (fr)
CA (1)	CA2434033A1 (fr)
CY (1)	CY1106915T1 (fr)
DE (1)	DE60221798T2 (fr)
DK (1)	DK1363668T3 (fr)
ES (1)	ES2287250T3 (fr)
MX (1)	MXPA03006631A (fr)
PT (1)	PT1363668E (fr)
SI (1)	SI1363668T1 (fr)
TW (1)	TW200744638A (fr)
WO (1)	WO2002058733A2 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6982251B2 (en)	2000-12-20	2006-01-03	Schering Corporation	Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en)	2001-01-26	2006-07-04	Schering Corporation	Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
CA2563051A1 (fr)	2001-01-26	2002-08-01	Schering Corporation	Combinaisons d'au moins un activateur de recepteurs actives de la proliferation des peroxysomes et d'au moins un inhibiteur de l'absorption des sterols, et traitements de troublesvasculaires
IL156422A0 (en)	2001-01-26	2004-01-04	Schering Corp	The use of substituted azetidinone compounds for the treatment of sitosterolemia
US7053080B2 (en)	2001-09-21	2006-05-30	Schering Corporation	Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
ATE345793T1 (de) *	2001-09-21	2006-12-15	Schering Corp	Behandlung von xanthom mittels azetidinon- derivate als hemmer der sterol absorption
US7056906B2 (en)	2001-09-21	2006-06-06	Schering Corporation	Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
GB0215579D0 (en)	2002-07-05	2002-08-14	Astrazeneca Ab	Chemical compounds
AR040588A1 (es)	2002-07-26	2005-04-13	Schering Corp	Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
EP2283837A3 (fr) *	2002-09-27	2011-04-20	Martek Biosciences Corporation	Acide docosahexaénoïque pour le traitement des inflammations sous-cliniques
WO2004043456A1 (fr)	2002-11-06	2004-05-27	Schering Corporation	Inhibiteurs d'absorption du cholesterol pour le traitement de la demyelination
JP2006519869A (ja)	2003-03-07	2006-08-31	シェーリング　コーポレイション	置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
ES2318274T3 (es) *	2003-03-07	2009-05-01	Schering Corporation	Compuestos de azetidinona sustituida, formulaciones y uso de los mismos para el tratamiento de hipercolesterolemia.
ATE406364T1 (de)	2003-03-07	2008-09-15	Schering Corp	Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US7459442B2 (en)	2003-03-07	2008-12-02	Schering Corporation	Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
WO2004094608A2 (fr) *	2003-04-18	2004-11-04	Curagen Corporation	Acides nucleiques et polypeptides apparentes a la procolipase humaine et leurs methodes d'utilisation
WO2005041978A1 (fr) *	2003-10-21	2005-05-12	Johns Hopkins University	Neuroprotection par le biais de composes au beta-lactame
EP1680189A2 (fr) *	2003-11-05	2006-07-19	Schering Corporation	Combinaisons de modulateurs lipidiques et d'azetidinones substituees et traitements d'affections vasculaires
DE602004020649D1 (de) *	2003-11-07	2009-05-28	Jj Pharma Inc	Hdl-verstärkende kombinationstherapie-komplexe
AU2004303742B2 (en)	2003-12-23	2008-06-19	Astrazeneca Ab	Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
PL1750862T3 (pl)	2004-06-04	2011-06-30	Teva Pharma	Kompozycja farmaceutyczna zawierająca irbesartan
US7838552B2 (en)	2004-06-04	2010-11-23	Forest Laboratories Holdings Limited	Compositions comprising nebivolol
US7803838B2 (en)	2004-06-04	2010-09-28	Forest Laboratories Holdings Limited	Compositions comprising nebivolol
SA06270191B1 (ar)	2005-06-22	2010-03-29	استرازينيكا ايه بي	مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
CA2615944A1 (fr) *	2005-07-18	2007-01-25	Reliant Pharmaceuticals, Inc.	Traitement au moyen d'inhibiteurs d'absorption de cholesterol a base d'azetidinone et d'acide gras omega-3 et produit de combinaison de ceux-ci
AR060623A1 (es)	2006-04-27	2008-07-02	Astrazeneca Ab	Compuestos derivados de 2-azetidinona y un metodo de preparacion
CA2757722C (fr)	2009-04-01	2018-05-22	Matrix Laboratories Ltd.	Procede enzymatique pour la preparation de la (s)-5-(4-fluorophenyl)-5-hydroxy-1-morpholin-4-yl-pentan-1-one, un intermediaire de l'ezetimibe et la conversion ulterieure en ezetim ibe
WO2011075539A2 (fr) *	2009-12-18	2011-06-23	Satiogen Pharmaceuticals, Inc.	Traitement de l'obésité ou du diabète avec des agents séquestrants des acides biliaires
TR201005327A2 (tr)	2010-06-30	2012-01-23	Bi̇lgi̇ç Mahmut	Sinerjik farmasötik formülasyonlar.
CN106573066A (zh)	2014-06-13	2017-04-19	联合治疗学有限公司	曲前列环素制剂

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3108097A (en) *		1963-10-22		Ehnojs
US2809194A (en) *		1957-10-08		Thiadiazine type natriuretic agents
US1286A (en) *		1839-08-13		Richard else
NL108640C (fr) *	1958-05-07
NL127065C (fr) *	1964-04-22
NL137318C (fr) *	1964-06-09
FI52570C (fi) *	1969-04-16	1977-10-10	Sumitomo Chemical Co	Menetelmä veren kolesteroli- tai lipoidipitoisuutta alentavien fenoxia lifaattisten karboksyylihappoyhdisteiden ja -esteriyhdisteiden valmist amiseksi.
US3692895A (en) *	1970-09-08	1972-09-19	Norman A Nelson	Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria
DE2230383C3 (de) *	1971-10-01	1981-12-03	Boehringer Mannheim Gmbh, 6800 Mannheim	Phenoxyalkylcarbonsäurederivate und Verfahren zur Herstellung derselben
US4148923A (en) *	1972-05-31	1979-04-10	Synthelabo	1-(3'-Trifluoromethylthiophenyl)-2-ethylaminopropane pharmaceutical composition and method for treating obesity
US3948973A (en) *	1972-08-29	1976-04-06	Sterling Drug Inc.	Halocyclopropyl substituted phenoxyalkanoic acids
US4626549A (en) *	1974-01-10	1986-12-02	Eli Lilly And Company	Treatment of obesity with aryloxyphenylpropylamines
US4179515A (en) *	1975-02-12	1979-12-18	Orchimed S. A.	Benzoylphenoxy propionic acid, esters thereof and pharmaceutical composition
US4235896A (en) *	1975-02-12	1980-11-25	Orchimed S.A.	Benzyl-phenoxy acid esters and hyperlipaemia compositions containing the same
JPS5195049A (en) *	1975-02-12	1976-08-20		* ********so*notsu***************************************nino
US4075000A (en) *	1975-05-27	1978-02-21	Eli Lilly And Company	Herbicidal use of 4-amino-3,3-dimethyl-1-phenyl-2-azetidinones
US4576753A (en) *	1975-10-06	1986-03-18	Fujisawa Pharmaceutical Co., Ltd.	Azetidinone compounds and processes for preparation thereof
US4304718A (en) *	1975-10-06	1981-12-08	Fujisawa Pharmaceutical Co., Ltd.	2-Azetidinone compounds and processes for preparation thereof
US4472309A (en) *	1975-10-06	1984-09-18	Fujisawa Pharmaceutical Co., Ltd.	2-Azetidinone compounds and processes for preparation thereof
US4166907A (en) *	1976-11-01	1979-09-04	E. R. Squibb & Sons, Inc.	3,3-Dichloro-2-azetidinone derivatives having antiinflammatory activity
US4144232A (en) *	1976-12-23	1979-03-13	Eli Lilly And Company	Substituted azetidin-2-one antibiotics
FR2403078A1 (fr) *	1977-09-19	1979-04-13	Lafon Labor	Nouveau procede de preparation de formes pharmaceutiques, cosmetiques ou de diagnostic
IT1157365B (it) *	1977-10-24	1987-02-11	Sandoz Ag	Medicamenti per trattare l'obesita' o ridurre il peso del corpo
US4250191A (en) *	1978-11-30	1981-02-10	Edwards K David	Preventing renal failure
US4375475A (en) *	1979-08-17	1983-03-01	Merck & Co., Inc.	Substituted pyranone inhibitors of cholesterol synthesis
US4260743A (en) *	1979-12-31	1981-04-07	Gist-Brocades N.V.	Preparation of β-lactams and intermediates therefor
US4444784A (en) *	1980-08-05	1984-04-24	Merck & Co., Inc.	Antihypercholesterolemic compounds
DE3107100A1 (de) *	1981-02-20	1982-09-09	Schering Ag, 1000 Berlin Und 4619 Bergkamen	Azaprostacycline, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
US4500456A (en) *	1981-03-09	1985-02-19	Eli Lilly And Company	Preparation of 4-fluoroazetidinones using FClO3
US4784734A (en) *	1981-04-10	1988-11-15	Otsuka Kagaku Yakuhin Kabushiki Kaisha	Azetidinone derivatives and process for the preparation of the same
US4602003A (en) *	1982-05-17	1986-07-22	Medical Research Foundation Of Oregon	Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia
US4602005A (en) *	1982-05-17	1986-07-22	Medical Research Foundation Of Oregon	Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
US4443372A (en) *	1982-06-23	1984-04-17	Chevron Research Company	1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators
US4534786A (en) *	1982-06-23	1985-08-13	Chevron Research Company	1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators
US4595532A (en) *	1983-02-02	1986-06-17	University Of Notre Dame Du Lac	N-(substituted-methyl)-azetidin-2-ones
CA1256650A (fr) *	1983-03-25	1989-06-27	Toshinari Tamura	Procede de production de composes de 2-azetidinone-4- substitue et medicaments les contenant
US4675399A (en) *	1983-03-28	1987-06-23	Notre Dame University	Cyclization process for β-lactams
DE3484362D1 (de) *	1983-03-28	1991-05-08	Ciba Geigy Ag	Verfahren zur herstellung von optisch aktiven azetidinonen.
WO1985004876A1 (fr) *	1984-04-24	1985-11-07	Takeda Chemical Industries, Ltd.	Derives de 2-azetidinone et leur procede de preparation
US4576749A (en) *	1983-10-03	1986-03-18	E. R. Squibb & Sons, Inc.	3-Acylamino-1-carboxymethylaminocarbonyl-2-azetidinones
US5229510A (en) *	1983-12-01	1993-07-20	Merck & Co., Inc.	β-lactams useful in determining the amount of elastase in a clinical sample
US5229381A (en) *	1983-12-01	1993-07-20	Merck & Co., Inc.	Substituted azetidinones as anti-inflammatory and antidegenerative agents
US4680391A (en) *	1983-12-01	1987-07-14	Merck & Co., Inc.	Substituted azetidinones as anti-inflammatory and antidegenerative agents
US4654362A (en) *	1983-12-05	1987-03-31	Janssen Pharmaceutica, N.V.	Derivatives of 2,2'-iminobisethanol
FR2561916B1 (fr) *	1984-03-30	1987-12-11	Lafon Labor	Forme galenique pour administration orale et son procede de preparation par lyophilisation d'une emission huile dans eau
US4581170A (en) *	1984-08-03	1986-04-08	E. R. Squibb & Sons, Inc.	N-hydroxyl protecting groups and process and intermediates for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
US4633017A (en) *	1984-08-03	1986-12-30	E. R. Squibb & Sons, Inc.	N-hydroxy protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
US4576748A (en) *	1984-09-17	1986-03-18	Merck & Co., Inc.	3-Hydroxy-3-aminoethyl β-lactams
US4620867A (en) *	1984-09-28	1986-11-04	Chevron Research Company	1-carbalkoxyalkyl-3-aryloxy-4-(substituted-2'-carboxyphenyl)-azet-2-ones as plant growth regulators and herbicides
AR240698A1 (es) *	1985-01-19	1990-09-28	Takeda Chemical Industries Ltd	Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US4642903A (en) *	1985-03-26	1987-02-17	R. P. Scherer Corporation	Freeze-dried foam dosage form
US4680289A (en) *	1985-06-05	1987-07-14	Progenics, Inc.	Treatment of obesity and diabetes using sapogenins
EP0234484B1 (fr) *	1986-02-19	1993-10-20	Sanraku Incorporated	Dérivés de l'azétidinone
GB8607312D0 (en) *	1986-03-25	1986-04-30	Ici Plc	Therapeutic agents
FR2598146B1 (fr) *	1986-04-30	1989-01-20	Rech Ind	Nouveau procede de preparation de fibrates.
DE3621861A1 (de) *	1986-06-30	1988-01-14	Laszlo Dr Med Ilg	Verwendung von aryloxycarbonsaeure-derivaten gegen dermatologische erkrankungen
FR2602423B1 (fr) *	1986-08-08	1989-05-05	Ethypharm Sa	Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede
US4814354A (en) *	1986-09-26	1989-03-21	Warner-Lambert Company	Lipid regulating agents
US4803266A (en) *	1986-10-17	1989-02-07	Taisho Pharmaceutical Co., Ltd.	3-Oxoalkylidene-2-azetidinone derivatives
US5229362A (en) *	1986-12-15	1993-07-20	Eli Lilly And Company	Antibiotic A10255 complex and factors, and process and production therefor
JPS63156788A (ja) *	1986-12-22	1988-06-29	Sanraku Inc	光学活性アゼチジノン類
US5110730A (en) *	1987-03-31	1992-05-05	The Scripps Research Institute	Human tissue factor related DNA segments
US4879301A (en) *	1987-04-28	1989-11-07	Hoei Pharmaceutical Co., Ltd.	Antiallergic and antiinflammatory benzothiazolinone derivatives
US5106833A (en) *	1987-07-23	1992-04-21	Washington University	Coagulation inhibitors
US5091525A (en) *	1987-10-07	1992-02-25	Eli Lilly And Company	Monohydrate and DMF solvates of a new carbacephem antibiotic
US4834846A (en) *	1987-12-07	1989-05-30	Merck & Co., Inc.	Process for deblocking N-substituted β-lactams
FR2627696B1 (fr) *	1988-02-26	1991-09-13	Fournier Innovation Synergie	Nouvelle forme galenique du fenofibrate
DE3807895A1 (de) *	1988-03-10	1989-09-21	Knoll Ag	Erzeugnisse, enthaltend einen calciumantagonisten und einen lipidsenker
GB8813012D0 (en) *	1988-06-02	1988-07-06	Norsk Hydro As	Non-b-oxidizable fatty acid analogues to reduce concentration of cholesterol & triglycerides in blood of mammals
US4952689A (en) *	1988-10-20	1990-08-28	Taisho Pharmaceutical Co., Ltd.	3-(substituted propylidene)-2-azetidinone derivates for blood platelet aggregation
US5073374A (en) *	1988-11-30	1991-12-17	Schering Corporation	Fast dissolving buccal tablet
US5112616A (en) *	1988-11-30	1992-05-12	Schering Corporation	Fast dissolving buccal tablet
US4876365A (en) *	1988-12-05	1989-10-24	Schering Corporation	Intermediate compounds for preparing penems and carbapenems
US5260305A (en) *	1988-12-12	1993-11-09	E. R. Squibb & Sons, Inc.	Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination
FR2640621B1 (fr) *	1988-12-19	1992-10-30	Centre Nat Rech Scient	N-aryl-azetidinones, leur procede de preparation et leur utilisation comme inhibiteurs des elastases
US4990535A (en) *	1989-05-03	1991-02-05	Schering Corporation	Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
JPH03108490A (ja) *	1989-06-30	1991-05-08	Shionogi & Co Ltd	フォスフォリパーゼａ↓２阻害物質
US5021461A (en) *	1989-07-26	1991-06-04	Merrell Dow Pharmaceuticals Inc.	Method of treating diabetes mellitus with bisphenol derivatives
US4983597A (en) *	1989-08-31	1991-01-08	Merck & Co., Inc.	Beta-lactams as anticholesterolemic agents
US5219574A (en) *	1989-09-15	1993-06-15	Cima Labs. Inc.	Magnesium carbonate and oil tableting aid and flavoring additive
US5178878A (en) *	1989-10-02	1993-01-12	Cima Labs, Inc.	Effervescent dosage form with microparticles
US5223264A (en) *	1989-10-02	1993-06-29	Cima Labs, Inc.	Pediatric effervescent dosage form
US5188825A (en) *	1989-12-28	1993-02-23	Iles Martin C	Freeze-dried dosage forms and methods for preparing the same
US5120729A (en) *	1990-06-20	1992-06-09	Merck & Co., Inc.	Beta-lactams as antihypercholesterolemics
US5120713A (en) *	1990-09-10	1992-06-09	Applied Research Systems Ars Holding N.V.	Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide
US5130333A (en) *	1990-10-19	1992-07-14	E. R. Squibb & Sons, Inc.	Method for treating type II diabetes employing a cholesterol lowering drug
US5190970A (en) *	1990-10-19	1993-03-02	E. R. Squibb & Sons, Inc.	Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
JP2640986B2 (ja) *	1990-11-08	1997-08-13	高砂香料工業株式会社	（１′ｒ，３ｓ）―３―（１′―ヒドロキシエチル）―アゼチジン―２―オン又はその誘導体の製造法
US5145684A (en) *	1991-01-25	1992-09-08	Sterling Drug Inc.	Surface modified drug nanoparticles
US5157025A (en) *	1991-04-01	1992-10-20	E. R. Squibb & Sons, Inc.	Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
US5162117A (en) *	1991-11-22	1992-11-10	Schering Corporation	Controlled release flutamide composition
US5278176A (en) *	1992-08-21	1994-01-11	Abbott Laboratories	Nicotine derivatives that enhance cognitive function
US5631365A (en) *	1993-09-21	1997-05-20	Schering Corporation	Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
WO1995035277A1 (fr) *	1994-06-20	1995-12-28	Schering Corporation	Composes d'azetidinone substitues utilises comme agent hypercholesterolemiant
JP3144624B2 (ja) *	1995-06-02	2001-03-12	杏林製薬株式会社	Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
GB9600464D0 (en) *	1996-01-09	1996-03-13	Smithkline Beecham Plc	Novel method
US20030153541A1 (en) *	1997-10-31	2003-08-14	Robert Dudley	Novel anticholesterol compositions and method for using same
AU779264B2 (en) *	1998-12-23	2005-01-13	G.D. Searle Llc	Combinations for cardiovascular indications
CA2423141A1 (fr) *	2000-09-27	2002-04-04	Merck & Co., Inc.	Derives d'acide benzopyrancarboxylique utilises pour le traitement du diabete et des troubles lipidiques
ATE338039T1 (de) *	2000-12-21	2006-09-15	Sanofi Aventis Deutschland	Diphenylazetidinonderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
IL156552A0 (en) *	2000-12-21	2004-01-04	Aventis Pharma Gmbh	Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
DK1345895T3 (da) *	2000-12-21	2007-05-07	Sanofi Aventis Deutschland	Hidtil ukendt diphenylazetidioner, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse til behandling af lipidstofskifteforstyrrelser
KR20080077033A (ko) *	2001-01-26	2008-08-20	쉐링 코포레이션	혈관 질환을 치료하기 위한 스테롤 흡수 억제제와 심혈관제제의 조합물
IL156422A0 (en) *	2001-01-26	2004-01-04	Schering Corp	The use of substituted azetidinone compounds for the treatment of sitosterolemia
CA2434488A1 (fr) *	2001-01-26	2002-08-01	Harry R. Davis	Combinaisons d'acide nicotinique et de derives de ce dernier, inhibiteur(s) d'absorption de sterols et traitements de conditions vasculaires
CA2563051A1 (fr) *	2001-01-26	2002-08-01	Schering Corporation	Combinaisons d'au moins un activateur de recepteurs actives de la proliferation des peroxysomes et d'au moins un inhibiteur de l'absorption des sterols, et traitements de troublesvasculaires
JP2004521124A (ja) *	2001-02-09	2004-07-15	メルク　エンド　カムパニー　インコーポレーテッド	糖尿病および脂質障害用の２−アリールオキシ−２−アリールアルカン酸類
WO2002081454A1 (fr) *	2001-04-09	2002-10-17	Dr. Reddy's Laboratories Ltd.	Derives d'acides aryliques et leur utilisation en medecine, procede de preparation de ces derives et compositions pharmaceutiques contenant lesdits derives

2002
- 2002-01-25 WO PCT/US2002/002010 patent/WO2002058733A2/fr active IP Right Grant
- 2002-01-25 AR ARP020100267A patent/AR035739A1/es not_active Application Discontinuation
- 2002-01-25 MX MXPA03006631A patent/MXPA03006631A/es active IP Right Grant
- 2002-01-25 EP EP07003151A patent/EP1785144A3/fr not_active Withdrawn
- 2002-01-25 JP JP2002559067A patent/JP2004521894A/ja active Pending
- 2002-01-25 EP EP02707556A patent/EP1363668B1/fr not_active Expired - Lifetime
- 2002-01-25 PT PT02707556T patent/PT1363668E/pt unknown
- 2002-01-25 DE DE60221798T patent/DE60221798T2/de not_active Expired - Fee Related
- 2002-01-25 ES ES02707556T patent/ES2287250T3/es not_active Expired - Lifetime
- 2002-01-25 TW TW096128030A patent/TW200744638A/zh unknown
- 2002-01-25 DK DK02707556T patent/DK1363668T3/da active
- 2002-01-25 US US10/057,534 patent/US20030053981A1/en not_active Abandoned
- 2002-01-25 AT AT02707556T patent/ATE369851T1/de not_active IP Right Cessation
- 2002-01-25 AU AU2002241956A patent/AU2002241956A1/en not_active Abandoned
- 2002-01-25 SI SI200230601T patent/SI1363668T1/sl unknown
- 2002-01-25 CA CA002434033A patent/CA2434033A1/fr not_active Abandoned
2007
- 2007-10-08 CY CY20071101283T patent/CY1106915T1/el unknown
2008
- 2008-06-11 US US12/136,985 patent/US20080261942A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1363668A2 (fr)	2003-11-26
DE60221798D1 (de)	2007-09-27
ATE369851T1 (de)	2007-09-15
EP1363668B1 (fr)	2007-08-15
AR035739A1 (es)	2004-07-07
ES2287250T3 (es)	2007-12-16
EP1785144A3 (fr)	2007-05-23
TW200744638A (en)	2007-12-16
SI1363668T1 (sl)	2007-12-31
AU2002241956A1 (en)	2002-08-06
WO2002058733A2 (fr)	2002-08-01
US20030053981A1 (en)	2003-03-20
WO2002058733A9 (fr)	2003-03-06
CA2434033A1 (fr)	2002-08-01
DE60221798T2 (de)	2008-06-05
WO2002058733A3 (fr)	2003-06-26
US20080261942A1 (en)	2008-10-23
JP2004521894A (ja)	2004-07-22
WO2002058733B1 (fr)	2003-08-14
PT1363668E (pt)	2007-11-07
MXPA03006631A (es)	2004-03-18
EP1785144A2 (fr)	2007-05-16
CY1106915T1 (el)	2012-09-26

Publication	Publication Date	Title
DK1363668T3 (da)	2007-11-05	Kombinationer af galdesyrekompleksdanner(e) og sterolabsorptionsinhibitor(er) og behandling af vaskulære indikationer
MXPA03006727A (es)	2003-10-24	Combinaciones de acido nicotinico y derivados del mismo con inhibidor(es) de la absorcion de los esteroles, y tratamiento para indicaciones vasculares.
IL190173A0 (en)	2008-08-07	Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
IL156488A0 (en)	2004-01-04	Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
HUP0401501A3 (en)	2012-02-28	Treating or preventing vascular inflammation using pharmaceutical compositions containing sterol absorption inhibitor(s)
DK1487541T3 (da)	2009-01-19	Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelse af perifere vaskulære sygdomme
DK1353696T3 (da)	2007-04-10	Kombinationer af peroxisomproliferatoraktiveret receptor (PPAR)-aktivator(er) og sterolabsorptionsinhibitor(er) og behandlinger til vaskulære indikationer
AU2003294483A8 (en)	2004-06-15	Devices and methods for treatment of vascular aneurysms
DK1379224T3 (da)	2009-11-09	Guanylat-cyclase receptor-agonister til behandling af vævsinflammation og carciogenese
DK1506041T3 (da)	2008-01-28	Inbandronsyre til behandling og forebyggelse af osteoporose
EP1379232A4 (fr)	2008-04-23	Composition de n-acetylcysteine et methodes de traitement et de prevention de la toxicite des medicaments
NO20041574L (no)	2004-05-28	Martensittisk rustfritt stal og fremgangsmate for fremstilling derav
DK1366269T3 (da)	2006-10-30	Forbedret elektronoverföringsmiddel i sammensætninger til syrebehandling af borehuller og tilhörende fremgangsmåder
EP1635815A4 (fr)	2009-03-25	Methodes et composes pour le traitement de la stenose vasculaire
NO20033854L (no)	2003-10-28	N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
DK1278540T3 (da)	2008-07-21	Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelsen af aterosklerose
IL158050A0 (en)	2004-03-28	Use of selective cox-2 inhibitors for the treatment of urinary incontinence
NO20042012L (no)	2004-07-16	Sammensetning og fremgangsmate for behandling av diabetes
ATE327752T1 (de)	2006-06-15	Aryl- (oder heteroaryl-) azolylcarbynolderivatve zur behandlung von harninkontinenz
DK1355668T3 (da)	2008-05-05	Anvendelse af IL-18 inhibitorer til behandling og/eller forebyggelsen af hjertesygdom
NO20033117L (no)	2003-09-04	Farmasöytiske blandinger som inhiberer vaskul¶r proliferasjon og metoder for anvendelse derav
DK1228026T3 (da)	2004-04-05	15-Hydroxyicosatetraensyrerelaterede forbindelser og fremgangsmåde til anvendelse
AU2003272189A1 (en)	2004-01-19	Caspase inhibitors for the treatment of diseases and conditions caused by exposure to radionuclides, biological agents, or chemical agents
AU2003285883A1 (en)	2004-05-04	Methods and compositions for determining risk of treatment toxicity
DK1379242T3 (da)	2012-09-17	Fremgangsmåde til behandling af cancer og sammensætninger til anvendelse derved